Tissue trafficking and target cell destruction in patients after infusion of TCR-transduced cells. (A) Biopsy of inflamed skin from DMF5 patient 2, day 5 after treatment, demonstrating spongiotic vesicles and necrotic/dyskeratotic keratinocytes (arrows), stained with hematoxylin and eosin, and immunohistochemically stained for CD8⁺ cells or the Melan-A antibody recognizing MART-1 antigen. (Bottom left) Positive control staining for the anti-MART-1 Melan-A antibody showing normal epidermal melanocytes and a subcutaneous melanoma deposit (original magnification ×20). (B) One week after treatment, biopsies from gp100(154) patient with preexistent patchy vitiligo, demonstrating CD8⁺ cellular infiltrate into the epidermis of pigmented, but not vitiliginous skin (original magnification ×20). (C) Slit-lamp ophthalmologic evaluation of DMF5 patient 5 eye, 2 weeks after treatment, demonstrating cloudy cellular anterior chamber infiltrate (above) and (below) with induced iris dilation 6 months after TCR treatment and steroid eye drop administration, demonstrating posterior synechiae (asymptomatic). (D) Cells present in ocular fluid from panel C (top), analyzed directly by staining and flow cytometry. (E) Audiologic examination of DMF5 patient 2 before TCR treatment, day 13 after treatment showing hearing loss, and 11 months after treatment, showing hearing recovery after intratympanic steroid treatment.